A phase 1/2 study of pexidartinib (AMG 509), a novel CSF-1R inhibitor, in patients with advanced solid tumors and tenosynovial giant cell tumor (TGCT)
Cited in blog · Journal of Clinical Oncology, 41(16_suppl), 11527-11527. · 2023
Uhm JH, Jones RL, Ravi V, et al. (2023). A phase 1/2 study of pexidartinib (AMG 509), a novel CSF-1R inhibitor, in patients with advanced solid tumors and tenosynovial giant cell tumor (TGCT). *Journal of Clinical Oncology*, 41(16_suppl), 11527-11527.
Authors
Uhm JH, Jones RL, Ravi V, et al.
Research lens
Uhm JH, Jones RL, Ravi V, et al. (2023). A phase 1/2 study of pexidartinib (AMG 509), a novel CSF-1R inhibitor, in patients with advanced solid tumors and tenosynovial giant cell tumor (TGCT). *Journal of Clinical Oncology*, 41(16_suppl), 11527-11527.
- blog
- novartis-pacibekitug-inflammation-2026-09-03